from the Quarterly:
Study review and next steps
As outlined in the recent announcement, the vehicle response seen with all US sites was unusually
two to four times higher than that seen in Australia, for both inflammatory and non-inflammatory
lesion reduction measures respectively. The Company is confident that the execution of the study
protocol was consistent across geographies and within geographies, whereas the manufacturing and
Phase 2 study supply was the key differences between the geographies. Botanix is actively
investigating the reasons for this unusual US response and is working with external experts in both
clinical management and manufacturing to review the study conduct, operations and materials.
from the Quarterly:Study review and next stepsAs outlined in the...
-
- There are more pages in this discussion • 11,001 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.055(16.9%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 38.0¢ | 33.0¢ | $7.103M | 19.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 134000 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 650314 | 19 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |